New York, NY – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services –…
New York, NY (May 1, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (KYMRIAH ®) for the treatment of large B-cell lymphoma after two or…
The lion’s share of donations still come in from licked envelopes with a stamp and a check inside, according to my own straw poll of a number of charities from Goodwill to my local food bank. In short, it’s outdated…
New York, NY (March 20, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) in combination with chemotherapy for the treatment of adults with previously untreated Stage III or IV classical…
Lymphoma Research Foundation Publishes White Paper to Outline Key Issues Discussed During Second Oral Therapies Workshop In October 2017, The Lymphoma Research Foundation (LRF) convened its second Adherence and Oral Therapies in Lymphoma and CLL Workshop with a diverse faculty to…
This month, the Lymphoma Research Foundation endorsed the bipartisan Cancer Care Planning and Communications (CCPC) Act. Co-Sponsored by U.S. Congressmen Mark DeSaulnier (D-CA) and Ted Poe (R-TX), the CCPC Act would establish a new Medicare service for cancer care planning. …
Lymphoma Research Foundation Launches Redesigned Site to Better Serve the Lymphoma and CLL Community New York, NY (March 2018) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding the most promising young lymphoma investigators…
Oral medications are being increasingly used to treat patients with lymphoma and chronic lymphocytic leukemia (CLL). Five oral drugs have been approved over the past three years for eight different indications in lymphoma and CLL. Many patients report numerous advantages…
New York, NY (October 19, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloleucel (YescartaTM, Kite, a Gilead Company) to treat patients with large B-cell lymphoma who have relapsed or have…
LRF Scientific Advisory Board Members to be Joined by Current and Former Grantees at the 59th ASH Annual Meeting & Exposition New York, NY (December 7, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively…